136 related articles for article (PubMed ID: 38614269)
21. The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer.
Albisinni S; Moussa I; Aoun F; Quackels T; Assenmacher G; Peltier A; Roumeguère T
Prog Urol; 2019 Apr; 29(5):270-281. PubMed ID: 30954405
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis.
Mori K; Janisch F; Mostafaei H; Lysenko I; Kimura S; Egawa S; Shariat SF
Urol Oncol; 2020 May; 38(5):315-333. PubMed ID: 32088103
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
24. The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
Hara T; Furukawa J; Okamura Y; Bando Y; Terakawa T; Harada K; Takahashi S; Nakano Y; Fujisawa M
Int J Urol; 2023 Sep; 30(9):779-786. PubMed ID: 37317886
[TBL] [Abstract][Full Text] [Related]
25. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
26. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Karakiewicz PI; Briganti A; Kimura S; Egawa S; Shariat SF
J Urol; 2020 Dec; 204(6):1129-1140. PubMed ID: 32716694
[TBL] [Abstract][Full Text] [Related]
27. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
Saito K; Urakami S; Komai Y; Yasuda Y; Kubo Y; Kitsukawa S; Okubo Y; Yamamoto S; Yonese J; Fukui I
BJU Int; 2012 Nov; 110(10):1478-84. PubMed ID: 22520732
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases: A retrospective cohort study.
Qin C; Liang EL; Du ZY; Qiu XY; Tang G; Chen FR; Zhang B; Tian DW; Hu HL; Wu CL
Medicine (Baltimore); 2017 May; 96(21):e6945. PubMed ID: 28538387
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic factors of upper tract urothelial carcinomas and impact on survival: a systematic review for the yearly scientific report of the French National Association of Urology].
Colin P; Irani J; Drouin SJ; Shariat SF; Rouprêt M
Prog Urol; 2014 Nov; 24(15):1000-10. PubMed ID: 25199726
[TBL] [Abstract][Full Text] [Related]
30. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N; Kikuchi E; Shirotake S; Kanao K; Matsumoto K; Kobayashi H; Miyazaki Y; Ide H; Obata J; Hoshino K; Hayakawa N; Ito Y; Kosaka T; Kodaira K; Oyama M; Miyajima A; Momma T; Nakagawa K; Ueno M; Oya M
Eur Urol; 2014 Jan; 65(1):227-34. PubMed ID: 23219372
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
[TBL] [Abstract][Full Text] [Related]
33. Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis.
Ishioka J; Saito K; Sakura M; Yokoyama M; Matsuoka Y; Numao N; Koga F; Masuda H; Fujii Y; Kawakami S; Kihara K
Br J Cancer; 2012 Sep; 107(7):1031-6. PubMed ID: 22918396
[TBL] [Abstract][Full Text] [Related]
34. Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Maiorano BA; Di Maio M; Cerbone L; Maiello E; Procopio G; Roviello G;
JAMA Netw Open; 2024 Mar; 7(3):e241215. PubMed ID: 38446479
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.
Takemura K; Fukushima H; Ito M; Kataoka M; Nakanishi Y; Sakamoto K; Suzuki H; Tobisu KI; Koga F
Urol Oncol; 2019 Feb; 37(2):108-115. PubMed ID: 30478012
[TBL] [Abstract][Full Text] [Related]
36. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
[TBL] [Abstract][Full Text] [Related]
37. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.
Grimm T; Buchner A; Schneevoigt B; Kretschmer A; Apfelbeck M; Grabbert M; Jokisch JF; Stief CG; Karl A
World J Urol; 2016 May; 34(5):703-8. PubMed ID: 26376992
[TBL] [Abstract][Full Text] [Related]
38. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies.
Wu S; Zhao X; Wang Y; Zhong Z; Zhang L; Cao J; Ai K; Xu R
Cell Physiol Biochem; 2018; 46(4):1352-1364. PubMed ID: 29689562
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma.
Xu H; Ai JZ; Tan P; Lin TH; Jin X; Gong LN; Lei HR; Yang L; Wei Q
Asian J Androl; 2020; 22(2):177-183. PubMed ID: 31169138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
